Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Earnings for Advaxis, Inc. (ADXS)
Earnings in 2023 (TTM): $-51,984,000
According to Advaxis, Inc.'s latest financial reports the company's current earnings (TTM) are $-51,984,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Advaxis, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-51,984,000 | $-48,072,000 |
| 2022 | $-14,309,000 | $-14,359,000 |
| 2021 | $-17,812,000 | $-17,862,000 |
| 2020 | $-26,419,000 | $-26,469,000 |
| 2019 | $-17,486,000 | $-17,792,000 |
| 2018 | $-66,465,000 | $-66,515,000 |
| 2017 | $-97,838,084 | $-93,435,402 |
| 2016 | $-76,091,855 | $-73,556,230 |
| 2015 | $-48,640,467 | $-47,031,118 |
| 2014 | $-18,882,194 | $-16,525,314 |
| 2013 | $-20,712,016 | $-19,986,826 |
| 2012 | $-12,416,474 | $-12,069,687 |
| 2011 | $-8,495,212 | $-8,115,740 |
| 2010 | $-11,091,178 | $-10,812,200 |
| 2009 | $7.22 K | $929.24 K |
| 2008 | $-5,405,155 | $-5,416,418 |
| 2007 | $-1,847,260 | $-2,454,453 |
| 2006 | $-5,760,444 | $-6,197,744 |
| 2005 | $-1,805,789 | $-1,805,789 |
| 2004 | $-533,847 | $-538,076 |
| 2003 | $-10,000 | $-10,000 |
| 2002 | $-10,000 | $-10,000 |